Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ACADEMIA
ACADEMIA
- JDS, JGS Publish 1st Guideline for Treatment of Diabetes in the Elderly
May 22, 2017
- PI/II Study Suggests Efficacy of Eisai’s Anti-Fractalkine Antibody for RA
April 25, 2017
- Gastric Cancer Guidelines Likely to Recommend Opdivo in 3rd Line Settings
April 24, 2017
- Hepatology Society to Release Updated Hep C Guidelines Soon, Reflecting Ximency Use
March 3, 2017
- NCC to Begin IIT for Pediatric ALL with Velcade Plus 5 Drugs
February 23, 2017
- AMED Drafts Japan’s First Manual for Treatment of Mitochondrial Diseases
February 20, 2017
- PCSK9 Inhibitors More Effective than Statins at Lowering LDL-C: New Atherosclerosis Prevention Guidelines
January 31, 2017
- Zonisamide Investigator-Led Trial for Dementia Symptoms to Begin in April
January 27, 2017
- OB-GYN Society Again Nudges Govt to Reinstate HPV Vaccine Recommendation
January 19, 2017
- Reinstate HPV Vaccine Recommendation ASAP: OB-GYN Society
December 28, 2016
- NIBIOHN Bioinformatics Specialist Hopeful About Use of AI in Building Drug Discovery Support System
December 19, 2016
- New Lung Cancer Guidelines to Give Keytruda Grade A Recommendation as First-Line Treatment
December 19, 2016
- Need for Resistance Testing a Factor in Selection of IFN-Free Therapies for Hep C: Hepatologist
November 22, 2016
- Draft Guidelines on Pneumonia Treatment Set Guides for Selecting Antibacterial Agents: Respiratory Society
November 7, 2016
- Cancer Society to Issue New Lung Cancer Treatment GL in December; Positioning of Anti-PD-1 Antibodies Will Be Focus of Interest
October 31, 2016
- Japan Lung Cancer Society Seeks Early 1st-Line Nod for Keytruda
October 26, 2016
- Saitama Medical Univ. Develops Jointly with Daiichi Sankyo New Antibody with Potential Application in Treatment of FOP
October 26, 2016
- 6 Drug Makers to Participate in “Drug Redirection Program” for Compounds in Development Limbo: Univ. of Tokyo’s Initiative
October 18, 2016
- Osteoporosis Experts Express “Shock” at Discontinuation of Development of Odanacatib
October 7, 2016
- Amendment to Personal Info Law Shouldn’t Stymie Epidemiology Studies: Doctors
September 27, 2016
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…